Incidences of breast cancer throughout long-term hormone replacement therapy

Journal of Steroid Biochemistry and Molecular Biology

Volumn 104, Issue 3-5, 2007, Pages 180-189

  Cortes Prieto J ^a   Juez Martel, P ^b  

^a UNIVERSITY OF ALCALÁ   (Spain)

^b UNIVERSIDAD NACIONAL DE EDUCACIÓN A DISTANCIA   (Spain)

Author keywords

Breast cancer; Cohort study; Hormone replacement therapy; Long term HRT

Indexed keywords

CONJUGATED ESTROGEN; MEDROXYPROGESTERONE ACETATE;

ADULT; ANTISYNTHETASE SYNDROME; ARTERY THROMBOSIS; ARTICLE; BREAST CANCER; BREAST TUMOR; CANCER INCIDENCE; CANCER RISK; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; COLLES FRACTURE; COLON CANCER; CONTROLLED STUDY; DIET; DRUG DOSE INCREASE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXERCISE; FEMALE; FOLLOW UP; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; LARYNX CANCER; LEG FRACTURE; LIPOSARCOMA; LONG TERM CARE; MAJOR CLINICAL STUDY; MENINGIOMA; MORBIDITY; OVARY TUMOR; PSYCHOPATHY; RIB FRACTURE; RISK ASSESSMENT; SPOTTING; TALUS FRACTURE; TREATMENT DURATION; VARICOSIS; VERTEBRA FRACTURE;

ADULT; AGE DISTRIBUTION; AGED; BREAST NEOPLASMS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; GANGLIOSIDES; HUMANS; INCIDENCE; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; TIME FACTORS;

EQUIDAE;

EID: 34250014960     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2007.03.033     Document Type: Article

References (26)

1. Marsden J. Hormone Replacement Therapy, the Menopause, and Breast Cancer. In: Pasqualini J.R. (Ed). Breast Cancer (2000), Marcel Dekker, New York-Basel 373-403 ISBN 0-8247.0712.5
2. Nachtigall L.E., Nachtigall R.H., Nachtigall R.D., and Beckman E.M. Estrogen Replacement Therapy II: A prospective Study in the Relationship to Carcinoma and Cardiovascular and Metabolic Problems. Obstet Gynecol 54 (1979) 74-79
3. Gambrell Jr. R.D., Mair R.C., and Sanders B.I. Decreased incidence of breast cancer in postmenopausal estrogen-progestogen users. Obstet Gynecol 62 (1983) 435-443
4. Byyny R.L., and Speroff L. The breast. In: Byyny R.L., and Speroff L. (Eds). A Clinical Guide for the Care of Older Women (1990), Williams & Wilkins Baltimore, Hong Kong, London, Sydney 133-156 ISBN 0-683-01150-2
5. Nachtigall M.J., Smilen S.W., Nachtigall R.D., Nachtigall R.H., and Nachtigall L.E. Incidence of breast cancer in a 22-year study of women receiving estrogen-progestin replacement therapy. Obstet. Gynecol. 80 (1992) 827-830
6. The writing group for the PEPI trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. J. Am. Med. Assoc. 273 (1995) 1999-2208.
7. Collaborative group on hormonal factors in breast cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52, 705 women with breast cancer and 108, 411 women without breast cancer. Lancet 350 (1997) 1047-1059.
8. Lando J.F., Heck K.F., and Brett K.M. Hormone replacement therapy and breast cancer risk in a nationally representative cohort. Am. J. Prev. Med. 17 (1999) 176-180
9. Ross R.K., Paganini-Hill A., Wan P.C., and Pike M.C. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J. Natl. Cancer Inst. 92 (2000) 328-332
10. Espié M., Toumant B., Cuvier C., and Cottu P.H. Épidémiologie des lésions malignes du sein. Encycl Méd Chir (2001), Editions Scientifiques et Médicales Elsevier SAS, Paris Gynécologie 840-A-15, p. 10
11. Magnusson C., Baron J.A., Correia N., Bergström R., Adami H.-O., and Persson I. Breast cancer risk following long-term oestrogen and estrogen-progestins-replacement therapy. Int. J. Cancer 81 (1999) 339-344
12. Li Ch I., Malone K.E., Porter P.L., Weiss N.S., Tang M.-T.C., Cushing-Haugen K.L., and Daling J.R. Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. J. Am. Med. Assoc. 289 (2003) 3254-3263
13. Eden J. Progestins and breast cancer. Am. J. Obstet. Gynecol. 188 (2003) 1123-1131
14. Salpeter S.R., Walsh M.E., Greyber E., Ormiston T.M., and Salpeter E.E. Mortality associated with hormone replacement therapy in younger and older women. J. Gen. Intern. Med. 19 (2004) 791-804
15. Goodman N., Goldzieher J., and Ayala C. Critique of the report from de Writing Group of the WHI. Menopausal Medicine of the American Society for Reproductive Medicine vol. 10 (2003) pp. 1-4
16. Pasqualini J.R., and Chetrite G.S. Recent insight on the control of enzyme involved in estrogen formation and transformation in human breast cancer. J. Steroid Biochem. Mol. Biol. 93 (2005) 221-236
17. Reed S.D., Voigt L.F., Beresford S.A.A., Hill D.A., Doherty J.A., and Weiss N.S. Dose of progestins in postmenopausal-combined hormone therapy and risk of endometrial cancer. Am. J. Obstet. Gynecol. 191 (2004) 1146-1151
18. McGuire W.L., and Clark L.G.M. Role of progesterone receptors in breast cancer. CA 36 (1986) 302
19. Armstrong B.K. Oestrogen therapy after the menopausal-boon or bone?. Med. J. Aust. 148 (1988) 213
20. Saeki T., Takashima S., Takeuchi M., Sano M., Honjo H., Sonoo H., Ochiai K., Komoike Y., Kobayashi T., Sawai K., Miyoshi Y., and Kobayashi S. Hormone replacement therapy (HRT) may not increase the incidence of breast cancer in Japan. Breast Cancer Res. Treatment 94 Suppl. 1 (2005) S159 (Abstract 3099)
21. Ostrzenski A., and Ostrzenska K.M. WHI clinical trial revisit: imprecise scientific methodology disqualifies the study's outcomes. Am. J. Obstet. Gynecol. 193 (2005) 1599-1604
22. van der Mooren M.J., and Kenemans P. The Million Women Study: a licence to kill other investigations. Eur. J. Obstet. Gynecol. Reprod. Biol. 113 (2004) 3-5
23. Sattin R.W., Rubin G.L., Webster L.A., Huezo C.M., Wingo P.A., Ory H.W., and Layde P.M. Family history and the risk of breast cancer. J. Am. Med. Assoc. 253 (1985) 1908
24. Constantino J.P., et al. Validation studies for models projecting the risk of invasive and total breast cancer. J. Natl. Cancer Inst. 91 (1999) 1541-1548
25. Mosca L., Manson J.E., Sutherland S.E., Langer R.D., Manolio T., and Barrett-Connor E. Cardiovascular disease in women: a statement for healthcare professionals from the American Heart Association. Circulation 96 (1997) 2468-2482
26. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. J. Am. Med. Assoc. 288 (2002) 321-333.